Abeona Therapeutics Inc. (ABEO) Stock Price Down 2.3%
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price was down 2.3% during mid-day trading on Monday . The stock traded as low as $4.16 and last traded at $4.21, with a volume of 68,026 shares. The stock had previously closed at $4.31.
Several equities analysts recently issued reports on ABEO shares. Maxim Group reissued a “buy” rating and set a $6.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, May 17th. Rodman & Renshaw reissued a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, May 18th. FBR & Co reissued a “buy” rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Finally, Zacks Investment Research lowered Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 24th.
The stock’s 50 day moving average price is $3.22 and its 200-day moving average price is $2.81. The company’s market cap is $140.89 million.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. On average, equities research analysts expect that Abeona Therapeutics Inc. will post ($0.71) earnings per share for the current fiscal year.
Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.